| 祁英,陈东基,马有国,等.吉西他滨诱导化疗后放疗同步联合卡培他滨治疗局部进展期胰腺癌的临床疗效[J].中华放射医学与防护杂志,2014,34(5):355-357.Qi Ying,Chen Dongji,Ma Youguo,et al.Induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with locally advanced pancreatic cancer[J].Chin J Radiol Med Prot,2014,34(5):355-357 |
| 吉西他滨诱导化疗后放疗同步联合卡培他滨治疗局部进展期胰腺癌的临床疗效 |
| Induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with locally advanced pancreatic cancer |
| 投稿时间：2013-07-11 |
| DOI：10.3760/cma.j.issn.0254-5098.2014.05.009 |
| 中文关键词: 局部进展期胰腺癌 放疗 诱导化疗 |
| 英文关键词:Locally advanced pancreatic cancer Radiotherapy Induction chemotherapy |
| 基金项目: |
|
| 摘要点击次数: 3451 |
| 全文下载次数: 2628 |
| 中文摘要: |
| 目的 评价吉西他滨诱导化疗后放疗同步联合卡培他滨治疗局部进展期胰腺癌（LAPC）的安全性及疗效。方法 对42例局部进展期胰腺癌用吉西他滨诱导化疗7周，每周1次，每次1000mg/m2，休息1周后开始放疗同步联合卡培他滨化疗，卡培他滨剂量为825mg/m2，2次/d，5d/周；放疗采用常规分割1.8~2.0Gy/次，中位照射剂量54Gy（34~64Gy）。结果 临床受益反应（CBR）20例，占47.6%；近期疗效：完全缓解（CR）2例，部分缓解（PR）8例，稳定（SD）27例，进展（PD）5例，中位生存时间10.1个月（4~36个月）；1年、2年生存率分别是38.2%和18.2%。骨髓抑制1~2级20例，3级以上5例；胃肠道不良反应1~2级22例，3级以上4例。结论 吉西他滨诱导化疗后再放化联合治疗局部进展期胰腺癌疗效较好，不良反应可耐受。 |
| 英文摘要: |
| Objective To evaluate the safety and efficacy of induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapywith capecitabine in patients with locally advanced pancreatic cancer (LAPC).Methods A total of 42 patients with locally advanced pancreatic cancer were enrolled.All patients received seven cycles of induction chemotherapy of gemcitabine 1 000 mg/m2, once a week.Concurrent chemoradiotherapy began 1 week after completion of induction chemotherapy.Radiotherapy was delivered with a median dose of 54 Gy (34-64 Gy) with 1.8-2.0 Gy in a fraction.The radiotherapy was combined with capecitabin at a dosage of 825 mg/m2 twice daily, 5 d/week.Results Twenty patients (47.6%) were evaluated as clinical benefit response (CBR).Two cases were observed with complete remission (CR), 8 with partial remission (PR), 27 with stable disease (SD), and 5 with progressive disease (PD).The median overall survival was 10.1 months (range of 4-36 months).The 1-, 2-year overall survival rate was 38.2% and 18.2%, respectively.Myelosuppression was recorded in 20 patients with grades 1-2, and 5 patients with grade 3.Twenty-two patients suffered from grade 1-2 gastrointestinal toxicities, while 4 patients suffered from grade 3.Conclusions The preliminary results showed that induction chemotherapy with gemcitabine followed by concurrent chemoradiotherapy with capecitabine in patients with LAPC might achieve encouraging efficacy with better tolerance. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|